Psychopharmacology Notes

Drugs and the Synapse

Drugs can significantly alter how we feel by impacting synaptic transmission, a complex process critical for neuronal communication. Understanding psychopharmacology involves exploring how various substances interact with synaptic mechanisms to produce their effects.

Synaptic Transmission Overview

Synaptic transmission involves various stages where numerous substances, including naturally occurring toxins and psychoactive chemicals, can influence the communication between neurons. The transmission process is critical for the functioning of the nervous system and is affected by the action of psychoactive substances used in the treatment of psychiatric conditions.

Synaptic Sequence

  1. Stimulation:

    • Strong stimulation generates an action potential, which is a rapid electrical signal that conveys information along the neuron.

    • Membrane Potential Changes: The resting potential of a neuron is −70-70 mV, with a threshold of −55-55 mV needed to trigger an action potential, peaking at +30+30 mV during depolarization.

  2. Axonal Propagation (Conduction):

    • The action potential propagates along the axon via a process called saltatory conduction, enabled by myelin sheaths that insulate segments of the axon and allow for efficient signal transmission at the Nodes of Ranvier.

    • Sodium (Na+Na^+) channels present at the Nodes facilitate the regeneration of the action potential, ensuring rapid transmission of signals.

  3. Synaptic Transmission Initiation:

    • Upon reaching the axon terminal, the action potential triggers synaptic transmission, which is the release of neurotransmitters from synaptic vesicles.

    • The influx of calcium ions (Ca2+Ca^{2+}) into the terminal, triggered by the action potential, is crucial for the fusion of vesicles with the presynaptic membrane.

  4. Neurotransmitter Release and Binding:

    • Neurotransmitter vesicles fuse with the membrane and release their contents into the synaptic cleft—the space between neurons.

    • Released neurotransmitters bind to specific receptors on the postsynaptic neuron, initiating a postsynaptic potential that can either excite or inhibit the neuron, depending on the nature of the neurotransmitter and the receptor type engaged.

  5. Neurotransmitter Inactivation and Recycling:

    • Several mechanisms ensure the termination of neurotransmitter activity:

      • Diffusion: Neurotransmitters may simply diffuse away, reducing their concentration in the synaptic cleft.

      • Enzymatic Degradation: Specific enzymes break down neurotransmitters (e.g., acetylcholinesterase for acetylcholine).

      • Re-uptake/Uptake: Neurotransmitters are actively transported back into the presynaptic neuron, recycling them for future use and conserving synthesis resources.

Neurotransmitters

  • Excitatory: Glutamate is the primary excitatory neurotransmitter, crucial for synaptic plasticity and learning.

  • Inhibitory: Gamma-Aminobutyric Acid (GABA) serves as the main inhibitory neurotransmitter, stabilizing neural activity and preventing over-excitation.

  • Mixed: Acetylcholine and dopamine can function as either excitatory or inhibitory, depending on the receptor subtype they interact with.

How Drugs Alter Synaptic Transmission

Drugs can influence multiple stages of synaptic transmission, including:

  • Propagation of the Action Potential: Certain drugs can either enhance or inhibit the generation of action potentials.

  • Neurotransmitter Release: Some substances modulate the release of neurotransmitters through various mechanisms, affecting overall neuronal communication.

  • Interaction with Postsynaptic Receptors: Drugs may mimic or block the effects of endogenous neurotransmitters at their receptor sites.

  • Inactivation and Recycling of the Transmitter: Certain medications can disrupt the breakdown or reuptake of neurotransmitters, increasing their availability in the synaptic cleft.

Examples of Substances and Their Mechanisms

  1. Action Potential Propagation Interference:

    • Tetrodotoxin (TTX): A potent toxin that blocks sodium channels in the axon, halting action potential propagation, resulting in paralysis and respiratory failure. It is notably 10,000 times more lethal than cyanide.

  2. Neurotransmitter Release Interference:

    • Tetanospasmin: A neurotoxin that inhibits GABA vesicle fusion, leading to reduced GABA release and causing an imbalance between excitation and inhibition, which manifests as muscle contractions characteristic of tetanus and can be fatal.

    • Botulinum Toxin (BOTOX): Blocks acetylcholine release at nicotinic synapses, preventing muscle contraction. It is used in cosmetic applications to reduce wrinkles by inhibiting muscle activity.

  3. Neurotransmitter Release Enhancement:

    • Amphetamine: Facilitates dopamine release by entering dopamine-releasing neurons and binding to dopamine transporters, leading to increased levels of dopamine in the synaptic cleft.

  4. Drugs Affecting Dopaminergic Pathways:

    • Several recreational drugs, including amphetamine, cocaine, heroin, and marijuana, particularly affect dopaminergic pathways, notably the pathway from the Ventral Tegmental Area (VTA) to the Nucleus Accumbens, which is integral for the sensations of pleasure, reward, and motivation.

  5. Interaction with Postsynaptic Receptors:

    • Curare: Acts as an antagonist, blocking acetylcholine from binding to nicotinic receptors, resulting in paralysis.

    • Heroin: Functions as an agonist of endorphins, binding to opiate receptors and leading to analgesia and relaxation.

    • THC (in Marijuana): An agonist of anandamide, it binds to cannabinoid receptors, influencing a broad range of effects including emotion, pain perception, appetite regulation, and memory.

    • Nicotine (in Tobacco): Stimulates nicotinic acetylcholine receptors, resulting in short-lived excitation followed by an increase in adrenaline levels.

  6. Interference with Transmitter Inactivation and Recycling:

    • Cocaine: Blocks the reuptake transporters for noradrenaline and dopamine, prolonging their action in the synaptic cleft.

Psychoactive Substances: Examples

  1. Chocolate:

    • Contains anandamide and phenylethylamine, albeit in minimal quantities. The pleasurable experience may contribute to its addictive qualities due to its flavor and the release of endorphins.

  2. Coffee:

    • Contains caffeine, which antagonizes adenosine receptors, diminishing the inhibitory effects of adenosine, and promotes catecholamine release, enhancing alertness.

    • Caffeine also inhibits phosphodiesterase, increasing cyclic adenosine monophosphate (cAMP) levels and promoting metabolic efficiency.

  3. Alcohol:

    • At low doses, acts as a GABA agonist, amplifying inhibitory synaptic transmission and inducing relaxation. At moderate doses, it indirectly stimulates the release of endorphins, leading to euphoria. However, high doses can result in severe sedation and impairment by binding to GABA channels. Very high levels may lead to neurotoxicity, resulting in cell death.

Psychoactive Substances Used to Treat Psychiatric Conditions

  1. Anxiety Disorders and GABA:

    • Symptoms often stem from deficits in GABAergic transmission. Medications like benzodiazepines (e.g., Valium) enhance GABA activity and thus alleviate anxiety symptoms.

  2. Depression:

    • Often linked to diminished levels of neurotransmitters, notably serotonin, dopamine, and noradrenaline. Treatments include MAO inhibitors, which prevent the breakdown of these neurotransmitters, and tricyclic antidepressants, which block their reuptake.

  3. Serotonin and Depression:

    • Selective Serotonin Reuptake Inhibitors (SSRIs) specifically target serotonin transporters, boosting serotonin availability without affecting other neurotransmitters, proving effective in managing depressive symptoms.

  4. Schizophrenia and Dopamine:

    • Characterized by an excess of dopamine activity. Neuroleptics (e.g., Haldol) function as dopamine antagonists, blocking receptors to mitigate the symptoms of psychosis such as paranoia and hallucinations without inducing receptor activation.

  5. Cocaine, Methamphetamine, and Amphetamine Derivatives:

    • These drugs reduce neurotransmitter reuptake and increase synaptic availability, intensifying effects and potentially inducing psychotic symptoms at high doses due to increased dopaminergic activity.

Side Effects

Drug effects are not isolated to target neurotransmitter systems; since neurotransmitters oversee various physiological processes, this can lead to numerous side effects. Medications like those for Parkinson’s disease and schizophrenia can exert opposing actions on dopamine pathways, sometimes aggravating symptoms from each condition when dosages are high.

Conclusions

Psychoactive substances exert their influence at various stages of the synapse, affecting both pre-synaptic and post-synaptic processes in complex ways. Examples include:

  • Pre-synaptic Processes:

    • Action potential conduction interference (e.g., TTX).

    • Neurotransmitter release modulation (e.g., botulinum toxin, tetanospasmin).

  • Post-synaptic Processes:

    • Receptor binding (e.g., nicotine).

    • Neurotransmitter breakdown inhibition (e.g., MAO inhibitors).

    • Reuptake interference (e.g., cocaine).
      Psychoactive substances act by mimicking the structure of neurotransmitters, allowing them to bind to receptors and induce physiological responses similar to those of naturally occurring neurotransmitters.

New Concepts

  • Agonist/Antagonist:

    • Compounds that either mimic (agonist) or inhibit (antagonist) the action of a neurotransmitter by binding to its receptor.

  • Competitive/Non-competitive:

    • Classification of agonists or antagonists based on whether they bind to the same site (competitive) or a different site (non-competitive) on the receptor channel.